Company: PSTV
Filing Date: 2025-07-21
Form Type: DEF 14A
Source: 0001140361-25-026611
Chunk: 68

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-21
Form: DEF 14A
Chunk 68
---
 Recommendation of the Board of Directors If a quorum is present, approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the potential issuance and sale of more than 20% of the Company’s issued and outstanding Common Stock pursuant to the Lincoln Park Purchase Agreement requires that a majority of the Common Stock having voting power present at the Annual Meeting or represented by proxy at the Annual Meeting are cast “FOR” approval. Abstentions will be counted as present for purposes of determining a quorum and are considered shares present and entitled to vote and thus will have the effect of a vote “AGAINST” this proposal. YOUR BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THIS PROPOSAL. 41

TABLE OF CONTENTS

PROPOSAL 3—THE REVERSE STOCK SPLIT PROPOSAL On May 2, 2025, at a special meeting of stockholders (the “Special Meeting”), our stockholders voted in favor of authorizing our Board to effect a reverse stock split of all of our outstanding shares of Common Stock at a specific ratio within a range of one-for-twenty five (1-for-25) to a maximum of one-for-two hundred fifty (1-for-250), (the “May 2025 Approval”). Our Board has unanimously approved and declared advisable and is recommending that our stockholders approve and adopt a proposed amendment to our Certificate of Incorporation to combine the outstanding shares of our Common Stock into a lesser number of outstanding shares, in substantially the form attached hereto as Appendix A, to effect an additional reverse stock split of all of our outstanding shares of Common Stock at a specific ratio within a range of one-for-two (1-for-2) to a maximum of a one-for-two hundred fifty (1-for-250), (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by our Board, in its sole discretion and without further action by the Company’s stockholders; provided, however, that our Board will not select a reverse split ratio that will result in us having fewer than 500,000 publicly held shares under the Nasdaq continued listing standards. The following table contains approximate information relating to our Common Stock immediately following the Reverse Stock Split under certain possible exchange ratios, based on share information as of June 18, 2025 (all share numbers are rounded